Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Although Merit Medical reported solid organic revenue and EBITDA growth, the manager highlights tariff headwinds in China as a key challenge that led to a downward revision of 2025 EPS guidance. The company hopes...
— Conestoga Capital Advisors, LLC
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Merit Medical Systems, Inc.